Jacobs Levy Equity Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $235M | Sell |
2,932,796
-182,054
| -6% | -$15M | 0.99% | 15 |
|
|
2025
Q4 | $266M | Buy |
3,114,850
+36,561
| +1% | +$3M | 1.03% | 16 |
|
|
2025
Q3 | $239M | Sell |
3,078,289
-362,226
| -11% | -$28.3M | 0.95% | 15 |
|
|
2025
Q2 | $269M | Sell |
3,440,515
-921,931
| -21% | -$68.8M | 1.06% | 14 |
|
|
2025
Q1 | $316M | Sell |
4,362,446
-252,717
| -5% | -$18.1M | 1.25% | 9 |
|
|
2024
Q4 | $342M | Buy |
4,615,163
+921,500
| +25% | +$64.5M | 1.21% | 11 |
|
|
2024
Q3 | $244M | Buy |
3,693,663
+2,606,950
| +240% | +$189M | 0.94% | 16 |
|
|
2024
Q2 | $100M | Sell |
1,086,713
-329,554
| -23% | -$29.2M | 0.42% | 55 |
|
|
2024
Q1 | $135M | Sell |
1,416,267
-977,496
| -41% | -$82.1M | 0.6% | 41 |
|
|
2023
Q4 | $183M | Buy |
2,393,763
+148,989
| +7% | +$10.4M | 0.92% | 18 |
|
|
2023
Q3 | $156M | Buy |
2,244,774
+582,028
| +35% | +$46.8M | 0.92% | 21 |
|
|
2023
Q2 | $157M | Buy |
1,662,746
+1,375,361
| +479% | +$120M | 0.9% | 21 |
|
|
2023
Q1 | $23.8M | Buy |
287,385
+83,031
| +41% | +$6.53M | 0.15% | 167 |
|
|
2022
Q4 | $15.2M | Buy |
+204,354
| New | +$15.7M | 0.1% | 218 |
|
|
2021
Q2 | – | Sell |
-3,132
| Closed | -$262K | – | 1055 |
|
|
2021
Q1 | $262K | Sell |
3,132
-4,772
| -60% | -$403K | ﹤0.01% | 944 |
|
|
2020
Q4 | $721K | Sell |
7,904
-70,229
| -90% | -$5.83M | 0.01% | 795 |
|
|
2020
Q3 | $6.24M | Buy |
78,133
+52,806
| +208% | +$4.12M | 0.06% | 298 |
|
|
2020
Q2 | $1.75M | Buy |
25,327
+21,667
| +592% | +$1.54M | 0.02% | 555 |
|
|
2020
Q1 | $230K | Hold |
3,660
| – | – | ﹤0.01% | 855 |
|
|
2019
Q4 | $285K | Sell |
3,660
-69,270
| -95% | -$5.41M | ﹤0.01% | 865 |
|
|
2019
Q3 | $5.35M | Buy |
+72,930
| New | +$5.12M | 0.07% | 329 |
|
|
2018
Q2 | – | Sell |
-5,160
| Closed | -$240K | – | 1046 |
|
|
2018
Q1 | $240K | Sell |
5,160
-257,736
| -98% | -$11.2M | ﹤0.01% | 898 |
|
|
2017
Q4 | $9.88M | Sell |
262,896
-307,161
| -54% | -$11.3M | 0.17% | 176 |
|
|
2017
Q3 | $20.8M | Sell |
570,057
-29,907
| -5% | -$1.14M | 0.4% | 72 |
|
|
2017
Q2 | $23.6M | Sell |
599,964
-312,180
| -34% | -$11.4M | 0.51% | 45 |
|
|
2017
Q1 | $28.6M | Sell |
912,144
-55,692
| -6% | -$1.74M | 0.58% | 34 |
|
|
2016
Q4 | $30.2M | Buy |
967,836
+161,277
| +20% | +$5.23M | 0.58% | 32 |
|
|
2016
Q3 | $32.4M | Buy |
806,559
+48,120
| +6% | +$1.81M | 0.58% | 31 |
|
|
2016
Q2 | $25.2M | Sell |
758,439
-48,645
| -6% | -$1.66M | 0.52% | 36 |
|
|
2016
Q1 | $23.7M | Sell |
807,084
-102,150
| -11% | -$2.82M | 0.5% | 40 |
|
|
2015
Q4 | $23.9M | Buy |
909,234
+6,090
| +0.7% | +$158K | 0.48% | 64 |
|
|
2015
Q3 | $21.4M | Sell |
903,144
-33,660
| -4% | -$812K | 0.44% | 72 |
|
|
2015
Q2 | $22.2M | Sell |
936,804
-132,000
| -12% | -$2.98M | 0.42% | 73 |
|
|
2015
Q1 | $25.4M | Buy |
1,068,804
+603,600
| +130% | +$13.5M | 0.43% | 67 |
|
|
2014
Q4 | $9.88M | Buy |
465,204
+3,444
| +0.7% | +$69.2K | 0.17% | 169 |
|
|
2014
Q3 | $7.86M | Buy |
+461,760
| New | +$7.29M | 0.13% | 192 |
|
|
2014
Q1 | – | Sell |
-664,740
| Closed | -$7.29M | – | 923 |
|
|
2013
Q4 | $7.29M | Buy |
+664,740
| New | +$7.49M | 0.11% | 231 |
|
Other funds holding EW
VCM
VPM
Jacobs Levy Equity Management's EW Position: Q1 2026 in Review
Jacobs Levy Equity Management reduced its Edwards Lifesciences (EW) stake by 5.8% in Q1 2026, selling an estimated $15M and leaving 2,932,796 shares worth $235M. The position accounts for 0.99% of the portfolio, ranked #15.
Jacobs Levy Equity Management first reported a position in EW in Q4 2013 and has held it in 37 quarters since. The position peaked at $342M in Q4 2024. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Jacobs Levy Equity Management held 2,932,796 shares of Edwards Lifesciences worth $235M as of Q1 2026.
- Jacobs Levy Equity Management sold 182,054 Edwards Lifesciences shares in Q1 2026, an estimated $15M.
- Edwards Lifesciences made up 0.99% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #15 holding.
- Jacobs Levy Equity Management first reported a position in Edwards Lifesciences in Q4 2013 and has held it in 37 quarters since.
- Jacobs Levy Equity Management's Edwards Lifesciences position peaked at $342M in Q4 2024.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.